PublizoomAward notice Supplies
Epoëtine Alfa
Notice published in Dutch. The AI analysis summarises it for you in your language.
- Public buyer
- VITAZ vzw
Sint-Niklaas - Place of performance
- 9100 Sint-Niklaas, East Flanders
- Amount awarded
- €1,920,000 excl. VAT
- Planned end of contract
- 19 May 2030
likely re-tender around November 2029 - Bids received
- 1
- Form
- Framework agreement
Multi-year contract: the buyer places orders as needs arise. - Procedure
- Open procedure
Any company may submit a bid. - Publication
- 4 June 2026
- Notice language
- Dutch
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Deze opdracht betreft het afsluiten van een raamovereenkomst met één opdrachtnemer waarbij alle voorwaarden voor de uitvoering van deze opdracht worden vastgelegd. Het doel van de raamovereenkomst is de levering van geneesmiddelen door de opdrachtnemer op afroep van de aanbesteders gedurende de looptijd beschreven in het bestek. Voor verdere toelichting verwijzen wij naar de technische bepalingen van het bestek.
Awarded to
- Sandoz NV BCE/KBO 0457.517.227
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33690000
Winning prices for comparable contracts
- A quarter below
- €444,216
- Median
- €606,904
- A quarter above
- €1,514,536
Amounts awarded (excl. VAT) over the last 3 years for 27 contracts in the same CPV group (3369…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Luspatercept VITAZ vzw · 22 October 2026 |
Orifarm Belgium | €3,000,000 |
| Ondansetron VITAZ vzw · 29 September 2026 |
Fresenius Kabi | €288,000 |
| Methotrexaat VITAZ vzw · 16 September 2026 |
Pharmanovia Benelux B.V. | €754,717 |
| Nintedanib VITAZ vzw · 17 July 2026 |
EG | €4,084,000 |
| Eltrombopag VITAZ vzw · 11 June 2026 |
ACCORD HEALTHCARE | €2,000,000 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 384328-2026.